Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Incyte Corporation - Common Stock (NQ:INCY)

117.67 +2.02 (+1.75%)
Streaming Delayed Price Updated: 3:13 PM EDT, Jul 21, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 897,319
Open 115.36
Bid (Size) 117.64 (400)
Ask (Size) 117.70 (200)
Prev. Close 115.65
Today's Range 114.80 - 118.95
52wk Range 67.17 - 119.60
Shares Outstanding 222,430,635
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
Incyte Corp (NASDAQ:INCY) Shows Value Stock Strength With Strong Fundamentals and Low Valuation ↗
Via Chartmill
News headline image
Incyte Data to Be Highlighted in Four Rapid Oral Presentations at the European Society for Medical Oncology (ESMO) Congress 2026 Support Efforts to Improve Outcomes in Difficult-to-Treat Cancers
From Incyte
Via Business Wire

Performance

YTD
+16.0%
+16.0%
1 Month
+13.5%
+13.5%
3 Month
+21.4%
+21.4%
6 Month
+14.7%
+14.7%
1 Year
+74.6%
+74.6%

More News

Read More
News headline image
Incyte (INCY): Buy, Sell, or Hold Post Q1 Earnings?
Via StockStory
Topics Stocks
News headline image
Incyte Presents Phase 1/2 Multidose Data for VGA039 (Latarcibart) at ISTH 2026, Showing Substantial Bleed Reductions in Patients with all Von Willebrand Disease Types
From Incyte
Via Business Wire
News headline image
Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks
Via StockStory
Topics Artificial Intelligence
Incyte Corp (NASDAQ:INCY) Screens as a Deep Value Opportunity with Strong Profitability ↗
Via Chartmill
News headline image
2 Fast-Growing Pharmaceutical Stocks to Buy Now ↗
Via The Motley Fool
News headline image
Incyte to Report Second Quarter Financial Results
From Incyte
Via Business Wire
News headline image
Incyte Completes Acquisition of Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio
From Incyte
Via Business Wire
News headline image
1 Mid-Cap Stock to Research Further and 2 We Avoid
Via StockStory
Topics Economy
Hormuz Goes Quiet, Software Wakes Up, and Burry Picks a Side ↗
Via Chartmill
News headline image
1 Cash-Producing Stock with Solid Fundamentals and 2 We Turn Down
Via StockStory
Topics Retirement
News headline image
2 Growth Stocks to Add to Your Roster and 1 We Avoid
Via StockStory
Topics Electric Vehicles
News headline image
Incyte Japan Announces Approval of Minjuvi® (tafasitamab) in Combination with Lenalidomide for the Treatment of Adults with Relapsed or Refractory Diffuse Large B-Cell Lymphoma (DLBCL)
From Incyte Biosciences Japan G.K.
Via Business Wire
Top S&P500 movers in Monday's session ↗
Via Chartmill
Monday's session: top gainers and losers in the S&P500 index ↗
Via Chartmill
Which S&P500 stocks are gapping on Monday? ↗
Via Chartmill
News headline image
Mirum Pharmaceuticals and Incyte Announce Positive Pivotal Phase 2 Results from PROGRESS Study of Zilurgisertib in Fibrodysplasia Ossificans Progressiva
From Mirum Pharmaceuticals, Inc. and Incyte
Via Business Wire
News headline image
Incyte Announces New Positive Data at EHA 2026 Showed INCA033989 Achieved Rapid, Robust and Sustained Clinical and Molecular Responses and Was Well Tolerated in Patients with Myelofibrosis and Essential Thrombocythemia
From Incyte
Via Business Wire
News headline image
Results from Incyte’s Pivotal Phase 3 frontMIND Trial of Tafasitamab (Monjuvi®/Minjuvi®) Combination Presented at the 2026 European Hematology Association (EHA) Congress Plenary Showed Prolonged Progression Free Survival
From Incyte
Via Business Wire
Top S&P500 movers in Wednesday's session ↗
Via Chartmill
News headline image
Why Incyte (INCY) Stock Is Up Today
Via StockStory
Topics Artificial Intelligence
News headline image
2 S&P 500 Stocks for Long-Term Investors and 1 Facing Challenges
Via StockStory
Topics Credit Cards Stocks
News headline image
Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles ↗
Via The Motley Fool
Topics Regulatory Compliance
News headline image
Incyte to Acquire Vega Therapeutics, a Wholly Owned Subsidiary of Star Therapeutics, Expanding its Hematology Portfolio into Bleeding Disorders
From Incyte
Via Business Wire

Frequently Asked Questions

Is Incyte Corporation - Common Stock publicly traded?
Yes, Incyte Corporation - Common Stock is publicly traded.
What exchange does Incyte Corporation - Common Stock trade on?
Incyte Corporation - Common Stock trades on the Nasdaq Stock Market
What is the ticker symbol for Incyte Corporation - Common Stock?
The ticker symbol for Incyte Corporation - Common Stock is INCY on the Nasdaq Stock Market
What is the current price of Incyte Corporation - Common Stock?
The current price of Incyte Corporation - Common Stock is 117.67
When was Incyte Corporation - Common Stock last traded?
The last trade of Incyte Corporation - Common Stock was at 07/21/26 03:13 PM ET
What is the market capitalization of Incyte Corporation - Common Stock?
The market capitalization of Incyte Corporation - Common Stock is 26.17B
How many shares of Incyte Corporation - Common Stock are outstanding?
Incyte Corporation - Common Stock has 26B shares outstanding.
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.